AA
PBYI icon

ALPS Advisors’s Puma Biotechnology PBYI Stock Holding History

ALPS Advisors’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-49,974
Closed -$350K – 953
2021
Q3 		$350K Sell
49,974
-3,182
-6% -$23.8K ﹤0.01% 733
2021
Q2 		$488K Sell
53,156
-19,674
-27% -$199K ﹤0.01% 522
2021
Q1 		$708K Buy
72,830
+1,115
+2% +$12.5K 0.01% 441
2020
Q4 		$736K Buy
71,715
+21,118
+42% +$214K 0.01% 425
2020
Q3 		$511K Sell
50,597
-3,102
-6% -$31.6K 0.01% 434
2020
Q2 		$560K Sell
53,699
-17,130
-24% -$177K 0.01% 437
2020
Q1 		$598K Sell
70,829
-8,262
-10% -$80.3K 0.01% 415
2019
Q4 		$692K Buy
79,091
+1,539
+2% +$12.7K 0.01% 462
2019
Q3 		$835K Sell
77,552
-3,248
-4% -$35.1K 0.01% 337
2019
Q2 		$1.03M Buy
+80,800
New +$1.86M 0.01% 324

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

ALPS Advisors's PBYI Position: Q4 2021 in Review

ALPS Advisors sold out of Puma Biotechnology (PBYI) in Q4 2021, closing a stake of 49,974 shares — an estimated $350K sold.

ALPS Advisors first reported a position in PBYI in Q2 2019 and held it in 10 quarters. The position peaked at $1.03M in Q2 2019. 102 funds tracked by Wall St. Rank hold PBYI as of Q4 2021.

  • ALPS Advisors reported no remaining Puma Biotechnology position as of Q4 2021 after selling out during the quarter.
  • ALPS Advisors sold 49,974 Puma Biotechnology shares in Q4 2021, an estimated $350K.
  • ALPS Advisors first reported a position in Puma Biotechnology in Q2 2019 and held it in 10 quarters.
  • ALPS Advisors's Puma Biotechnology position peaked at $1.03M in Q2 2019.
  • 102 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2021.

Based on ALPS Advisors's 13F filing for Q4 2021, filed 9 Feb 2022.